PROPHYLACTIC SUBCUTANEOUS MASTECTOMY IN HEREDITARY TRIPLE-NEGATIVE BREAST CANCER
- Authors: ZIKIRYAKHODZHAEV A.D1, RASSKAZOVA E.A1, FROLOVA M.A2, IGNATOVA E.O2
-
Affiliations:
- P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
- Issue: No 6 (2014)
- Pages: 101-104
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247245
- ID: 247245
Cite item
Abstract
Full Text
About the authors
A. D ZIKIRYAKHODZHAEV
P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia
Email: azizz@mail.ru
PhD, head of the Department of Oncology and reconstructive surgery of the mammary gland and skin 125284, Russia, Moscow, 2nd Botkinsky proezd 3
E. A RASSKAZOVA
P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia
Email: rasskaz2@yandex.ru
PhD, a researcher at the Department of Oncology and reconstructive surgery of the mammary gland and skin 125284, Russia, Moscow, 2nd Botkinsky proezd 3
M. A FROLOVA
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Email: drfrolova@yandex.ru
PhD, Senior Research Assistant, Department of Clinical Pharmacology and Chemotherapy 115478, Russia, Moscow, Kashirskoye shosse 24
E. O IGNATOVA
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Email: md.ignatova@gmail.com
PhD student, Department of Clinical Pharmacology and Chemotherapy 115478, Russia, Moscow, Kashirskoye shosse 24
References
- Пономарева О.В. Современные представления о возможностях лекарственной терапии пациенток с тройным негативным раком молочной железы (ASKO 2011). Онкология. 2011; 13(3): 214-21
- Тюляндин С.А., Стенина М.Б., Фролова М.А. Тройной негативный рак молочной железы. Практическая онкология. 2010; 11(4): 247-52
- Dar-Esfahani S., Loibl S., Müller B.M., Roller M., Denkert C., Komor M. et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and her2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res. 2009; 11(5): R69.
- Torrisi R., Balduzzi A., Ghisini R., Rocca A., Bottiglieri L., Giovanardi F. et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother. Pharmacol. 2008; 62(4): 667-72